Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Rona Smith
High-dose vitamin D does not improve survival on dialysis
High-dose vitamin D does not improve survival on dialysis October 30, 2026 2 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
A pragmatic, randomised, open-label, multi-centre UK registry-facilitated trial evaluating the effect of high-dose cholecalciferol on mortality in patients on dialysis: the SIMPLIFIED trial | Trials | Full Text
Participants randomised to the control group will receive standard care based on local treatment guidelines but will not be permitted to receive cholecalciferol or ergocalciferol > 1000 IU per day for the duration of the study, unless vitamin D deficiency-related osteomalacia is diagnosed. Patients randomised to receive cholecalciferol will be prescribed cholecalciferol 60,000 IU fortnightly, in addition to standard care.
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
Discussion This international, randomised, controlled trial demonstrated that rituximab was superior to azathioprine for prevention of disease relapse in patients with AAV with a prior history of relapse, following reinduction of remission with rituximab and glucocorticoids, and there was lower average glucocorticoid exposure in the rituximab group.
Using a Network-Based Analysis Approach to Investigate the Involvement of S. aureus in the Pathogenesis of Granulomatosis with Polyangiitis
Altmetric share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up ... Endorse textsms ... Comment Need Help? Support Find support for a specific problem in the support section of our website. Get Support Feedback Please let us know what you think of our products and services. Give Feedback Information Visit our dedicated information section to learn more about MDPI.
Response to: ‘Correspondence on ‘Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis’’ by Parikh et al
http://orcid.org/0000-0002-7438-5156Rona M Smith1,2, Peter A Merkel3, David Jayne1,2 1 Department of Nephrology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK 2 Department of Nephrology, University of Cambridge, Cambridge, UK 3 Division of Rheumatology, Department of Medicine and Division of Clinical Epidemiology, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA Correspondence to Dr Rona M Smith,...
The Role of Sural Nerve Biopsy in the Diagnosis of Vasculitis
DISCUSSION The comparability of our results with previously published studies of biopsy for the diagnosis of peripheral nerve vasculitis is limited by differences in vasculitis pathology criteria and unclearly described recruitment methods.5,12,18,19 In this study, histopathological vasculitis was categorized as definite or probable in accordance with the 2015 Brighton Collaboration reinterpretation and update of the Peripheral Nerve Society guidelines for vasculitic neuropathy,16,17 enabling...
The Role of Sural Nerve Biopsy in the Diagnosis of Vasculitis
This study was supported by grants from the Swedish Research Council (Vetenskapsrådet: 2019-01655), and the Faculty of Medicine, Lund University (ALF-medel). K. Gisslander, MSc, Department of Rheumatology, Lund University, Lund, Sweden; L.B. Dahlin, MD, PhD, Department of Translational Medicine - Hand Surgery, Lund University, Malmö, Sweden; R. Smith, MD, PhD, D.
Alemtuzumab for Refractory Primary Systemic Vasculitis
Abstract and Introduction Abstract Background: Primary systemic vasculitis (PSV) is a heterogeneous group of autoimmune conditions. There is an unmet need for alternative therapies that lead to sustained remission in patients with refractory disease.
Response to: ‘Correspondence on ‘Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis’’ by Parikh et al
Response to: ‘Correspondence on ‘Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis’’ by Parikh et al Free http://orcid.org/0000-0002-7438-5156Rona M Smith1,2, Peter A Merkel3, David Jayne1,2 1Department of Nephrology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK 2Department of Nephrology, University of Cambridge, Cambridge, UK 3Division of Rheumatology, Department of Medicine and Division of Clinical Epidemiology, Department of...
At least 2 years of maintenance rituximab remains ‘reasonable option’ for ANCA vasculitis
May 22, 2021 3 min read Save Source/Disclosures Published by: Source: Smith R. Maintenance rituximab in ANCA-associated vasculitis: Dose, frequency, and duration – how do we decide? Presented at: Biologic Therapies Summit IX; May 21-23, 2021 (virtual meeting). Disclosures: Smith reported no relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on .
Response to: ‘Correspondence on ‘Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis’’ by Parikh et al
Response to: ‘Correspondence on ‘Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis’’ by Parikh et al Free http://orcid.org/0000-0002-7438-5156Rona M Smith1,2, Peter A Merkel3, David Jayne1,2 1Department of Nephrology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK 2Department of Nephrology, University of Cambridge, Cambridge, UK 3Division of Rheumatology, Department of Medicine and Division of Clinical Epidemiology, Department of...
Rituximab successfully re-induces remission after ANCA-associated vasculitis relapse
July 21, 2020 2 min read Save Source/Disclosures ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis http://orcid.org/0000-0002-7438-5156Rona M Smith1,2, http://orcid.org/0000-0003-4790-283XRachel Bronwen Jones2, Ulrich Specks3, Simon Bond4, http://orcid.org/0000-0002-0333-8918Marianna Nodale4, Reem Aljayyousi5, Jacqueline Andrews6, Annette Bruchfeld7, Brian Camilleri8, Simon Carette9, Chee Kay Cheung10, Vimal Derebail11, Tim Doulton12, Lindsy Forbess13, Shouichi Fujimoto14, Shunsuke Furuta15, Ora...
Acute kidney injury as the presenting complaint of ceftazidime-induced immune-mediated haemolysis
Unexpected outcome (positive or negative) including adverse drug reactions Acute kidney injury as the presenting complaint of ceftazidime-induced immune-mediated haemolysis Ashley Ferro1, Meryl Griffiths2, Rona Smith1 and Andrew Fry1 1 Department of Nephrology, Addenbrooke's Hospital, Cambridge, UK 2 Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK Correspondence to Dr Ashley Ferro; ashley.ferro{at}addenbrookes.nhs.uk Abstract We present the case of ceftazidime-induced...
Repeat rituximab superior to azathioprine for preventing relapse in ANCA-associated vasculitis
ATLANTA — Treatment with repeat doses of rituximab is superior to daily azathioprine for preventing relapse among patients with ANCA-associated vasculitis with a history of relapse, according to data presented at the 2019 ACR/ARP Annual Meeting.
Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients
Original Article Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients Federico Alberici MD, PhD Address correspondence to Federico Alberici, MD, PhD, University of Milan, ASST Santi Paolo e Carlo, San Carlo Borromeo Hospital, 20153 Milan, Italy. E‐mail: federico.alberici@gmail.com. PDF PDF Share The full text of this article hosted at iucr.org is unavailable due to technical difficulties.
Arnetta Henderson is the only qualified candidate for COM trustee
The May 6 election is one of the most important in the history of the College of the Mainland. Like many other people, I am voting for Arnetta Henderson for College of the Mainland board of trustees Position 7 At Large. Arnetta is running for this position because she is committed to restoring quality, affordable education for students in our community. She is far more qualified to serve as a trustee than her opponent.
Progressive multifocal leucoencephalopathy with Behçet’s disease: an insight into pathophysiology
Sir, We report a case of progressive multifocal leucoencephalopathy (PML) with Behçet’s disease (BD), after immunomodulatory agents, including rituximab and alemtuzumab. We studied our patient’s immunological response, contrasting with a cohort (n = 27) of relapsing–remitting multiple sclerosis (RRMS) patients. A 33-year-old, right-handed woman with a 10-year prodrome was diagnosed with BD in 2005.
Article on COM union was biased, at best - The Galveston County Daily News: Guest Columns
College of the Mainland has been in crisis for several years. Many people know about the wrongful terminations, mistreatment of employees, racism, lawsuits, massive legal expenses and decline of educational quality. Only one group on campus has stood up for employees and students — COM-Unity, the employee union.
Beth Lewis is what's 'wrong' with COM - The Galveston County Daily News: Guest Columns
I wasn’t surprised to read that the College of the Mainland board of trustees may not renew President Beth Lewis’s contract. But the article stating the community supports Lewis was terribly misleading (“Community urges trustees to reconsider COM president’s contract,” The Daily News, April 5). The people backing Lewis at the recent board meeting don’t represent most in the community. Why didn’t the reporter ask longtime critics, local union members and other people for their opinions?
COM got it wrong on faculty tenure - The Galveston County Daily News: Guest Columns
Trustees Rachel Delgado, Rosalie Kettler, Roney McCrary and Wayne Miles have seriously damaged College of the Mainland and the community by ending tenure for new faculty members. Michael A. Smith’s recent editorial did an excellent job explaining why this decision will be disastrous for professors, students and the quality of education at the college (“Curtailing tenure a bad move for College of the Mainland,” The Daily News, Oct. 28).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Rona
Contact Rona, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack